You are here
Pfizer Oncology Press Kit
PLEASE NOTE: All assets on this page are intended for use by media professionals.
At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference on the lives of patients. Today, Pfizer Oncology has an industry-leading portfolio of 14 approved cancer medicines across 22 indications, including breast, prostate, kidney, lung and hematology. We also have two oncology biosimilar medicines approved globally and several assets in mid to late-stage development for the treatment of cancer or as supportive care. Pfizer Oncology is striving to change the trajectory of cancer.
For the latest information on our growing pipeline, product portfolio and collaborations with the broader cancer community, visit this page periodically for leadership perspective, fact sheets, videos and other media resources. We also encourage you to visit our other online resources for additional information on Pfizer Oncology.
CHANGING THE TRAJECTORY OF CANCER TAKES FOCUS – AT SCALE
Andy Schmeltz, Global President and General Manager, Pfizer Oncology
MAPPING THE FUTURE ONCOLOGY LANDSCAPE: HOW WE CAN BUILD UPON IMMUNO-ONCOLOGY
Chris Boshoff, MD, PhD, Senior Vice President and Head of Immuno-Oncology, Translational Oncology and Early Development